Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. (Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE–TIMI 58 Investigators) N Engl J Med 2019 Jan 24;380(4):347-357 PMID: 30415602 SCOPUS ID: 2-s2.0-85060042753 11/13/2018 5181 Citations